A Bold

TG-1701 is an investigational oral, once-daily BTK inhibitor that irreversibly binds to and inhibits Bruton’s tyrosine kinase (BTK), a crucial driver of B-cell proliferation.

B-cell receptor (BCR) signaling drives normal B-cell development and supports the growth and survival of malignant B-cells. Targeting BTK has been validated as an important therapeutic strategy for select B-cell malignancies including CLL and NHL.

A phase 1 study evaluating TG-1701 as a single agent alone and in combination with ublituximab and umbralisib in patients with CLL and NHL is ongoing.